Genmab — November 2019
-
I april 2019 blev sc versionen af BCMA/CD3 introduceret https://clinicaltrials.gov/ct2/show/NCT03145181?term=Bcma+cd3&draw=2&rank=2 Er det kommet frem om om det er i rendyrket form eller med HALOs Enhanze - ikke nævnt i forsøget så sikkert ren form. Der foreligger sikkert resultater fra 60 pts med iv - apropos late breaker ash.
-
Genmab has been chosen as a finalist for the 2019 IPO of the Year and 2019 CEO of the Year categories by the European Lifestars Awards.
https://www.linkedin.com/posts/genmab_genmab-has-been-chosen-as-a-finalist-for-activity-6602260933177860096-4yhc -
https://clinicaltrials.gov/ct2/show/NCT04108195?term=MMY1002&draw=2&rank=2 I dette forsøg, der sikkert er startet, kombineres dara-sc med de to duobodies hos JNJ, som Genmab har udviklet. Disse indgives iv pt. Men HALO har udlicenseret deres ENHANCE til bl.a. Roche, hvor to stoffer blandes i en sc dosis. Så teortisk kunne behandling med disse kombinationer blive en 5 min sc-version.
-
Godmorgen.
-
God morgen
-
-
Pensionist: Søg på Peter12 - og du finder dette. https://www.proinvestor.com/investors/52766/peter12
-
Google er lynhurtig og mere præcis end vores egen søgemaskine i debatten. Skriv "Proinvestor debat emne eller selskabsnavn" Vupti så finder man det man søger.
-
Dara/rev/dex godkendt i EU
-
first problem was that the back-neck program was stuck in the back and forth at the same place in the neck and the program could only be closed by turning off the power. The second bible was with the large program neck-back-loins, it also ended with clinging to the neck back and forth and could not be ended without a power cut. The latest problem is, in the back-lumbar program, here the shake has disappeared so it only has massage, in the sequences where there is usually shaking there is a stay
-
-
GENMAB FÅR JA FRA EU-KOMMISSIONEN TIL DARZALEX-KOMBINATION
17:32
EU-Kommissionen har givet Genmab markedsføringstilladelse til Darzalex i kombination med kræftmidlet Revlimid og dexamethasone til behandling af voksne med nydiagnosticeret knoglemarvskræft.Det fremgår tirsdag aften af en fondsbørsmeddelelse fra selskabet.
Dermed følger EU-Kommissionen indstillingen fra CHMP, der er et udvalg under de europæiske sundhedsmyndigheder, EMA, som blev givet i oktober.
/ritzau/FINANS
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind